Skip to Content
Merck
CN

Key Documents

View All Documentation

SML1265

Bosentan hydrate

≥98% (HPLC), endothelin receptor antagonist, powder

Synonym(s):

4-(1,1-Dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2′-bipyrimidin]-4-yl]benzenesulfonamide monohydrate, 4-Tert-butyl-N- [6-(2-hydroxyethoxy)-5-(2-methoxy-phenoxy)-[2,2´]-bipyrimidin-4-yl]-benzenesulfonamide monohydrate, Ro-47-0203

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C27H29N5O6S · H2O
CAS Number:
157212-55-0
Molecular Weight:
569.63
UNSPSC Code:
12352200
PubChem Substance ID:
329825756
NACRES:
NA.77
MDL number:
MFCD09751188
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Bosentan hydrate, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

O=S(C1=CC=C(C(C)(C)C)C=C1)(NC2=NC(C3=NC=CC=N3)=NC(OCCO)=C2OC4=CC=CC=C4OC)=O.O

InChI

1S/C27H29N5O6S.H2O/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24;/h5-15,33H,16-17H2,1-4H3,(H,30,31,32);1H2

InChI key

SXTRWVVIEPWAKM-UHFFFAOYSA-N

Application

Bosentan hydrate has been used in cell viability assay. It has also been used as a positive control for calcium transient analysis.

Biochem/physiol Actions

Bosentan is found to decrease deposition of collagen in the lungs, which has been observed in bleomycin-induced pulmonary fibrosis rat model.
Bosentan is a endothelin receptor antagonist; antihypertensive; pulmonary hypertension treatment.
Bosentan is an endothelin receptor antagonist. Endothelin is a potent vasoconstrictor, making antagonists of clinical interest for the treatment of conditions associated with vasospasm, such as subarachnoid hemorrhage (SAH) and hypertension. Bosentan is a dual endothelin receptor antagonist effective in the treatment of pulmonary arterial hypertension (PAH), the first of the class to make it to market. Bosentan is an orally available, competitive antagonist of both the ETA and ETB receptor subtypes with a Ki of 4.7 nM for ETA and a Ki of 95 nM for ETB.

pictograms

Health hazard
GHS08

signalword

Warning

Hazard Classifications

Aquatic Chronic 3 - Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
075M4770V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Molecular phenotyping combines molecular information, biological relevance, and patient data to improve productivity of early drug discovery.
Drawnel F M, et al.
Cell Chemical Biology, 24(5), 624-634 (2017)
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
Russignan A, et al.
British Journal of Haematology, 178(5), 781-793 (2017)
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
King Jr T E, et al.
American Journal of Respiratory and Critical Care Medicine, 177(1), 75-81 (2008)
View All Related Papers

Global Trade Item Number

SKUGTIN
SML1265-10MG04061832900322
SML1265-50MG04061832900339